StreetInsider.com News Articles

Cortexa Advances Commercialisation of MDMA Supply in Australia

Mon, 23 Mar 2026 09:00:00 -0400

MELBOURNE, Australia, March 23, 2026 (GLOBE NEWSWIRE) -- Cortexa (Cortexa or the Company), a leading psychedelic medicines supplier, reaffirms its market leading position in FY2026 for MDMA (3,4-methylenedioxymethamphetamine).

Cortexa is a 50/50 joint venture between PharmAla Biotech (CSE: MDMA) and Vitura Health (ASX: VIT). Following completion of the world’s largest (and first Australian) GMP batch of MDMA capsules earlier this financial year, the Company has secured supply arrangements with authorised providers nationally to support clinical programs and patient treatment under Australia’s regulated prescribing pathways.

Through Cortexa market activities, the majority of the initial batch has now

Cortexa Advances Commercialisation of MDMA Supply in Australia

Mon, 23 Mar 2026 09:00:00 -0400

Through Cortexa market activities, the majority of the initial batch has now

Cortexa Advances Commercialisation of MDMA Supply in Australia

Mon, 23 Mar 2026 09:00:00 -0400

Through Cortexa market activities, the majority of the initial batch has now

Cortexa Advances Commercialisation of MDMA Supply in Australia

Mon, 23 Mar 2026 09:00:00 -0400

Through Cortexa market activities, the majority of the initial batch has now

Cortexa Advances Commercialisation of MDMA Supply in Australia

Mon, 23 Mar 2026 09:00:00 -0400

Through Cortexa market activities, the majority of the initial batch has now

Cortexa Advances Commercialisation of MDMA Supply in Australia

Mon, 23 Mar 2026 09:00:00 -0400

Through Cortexa market activities, the majority of the initial batch has now

Cortexa Advances Commercialisation of MDMA Supply in Australia

Mon, 23 Mar 2026 09:00:00 -0400

Through Cortexa market activities, the majority of the initial batch has now

Cortexa Advances Commercialisation of MDMA Supply in Australia

Mon, 23 Mar 2026 09:00:00 -0400

Through Cortexa market activities, the majority of the initial batch has now

Cortexa Advances Commercialisation of MDMA Supply in Australia

Mon, 23 Mar 2026 09:00:00 -0400

Through Cortexa market activities, the majority of the initial batch has now

Cortexa Advances Commercialisation of MDMA Supply in Australia

Mon, 23 Mar 2026 09:00:00 -0400

Through Cortexa market activities, the majority of the initial batch has now

Cortexa Advances Commercialisation of MDMA Supply in Australia

Mon, 23 Mar 2026 09:00:00 -0400

Through Cortexa market activities, the majority of the initial batch has now

Cortexa Advances Commercialisation of MDMA Supply in Australia

Mon, 23 Mar 2026 09:00:00 -0400

Through Cortexa market activities, the majority of the initial batch has now

PharmAla Files Audited Financials for Year Ending August 31, 2023

Fri, 29 Dec 2023 16:00:00 -0400

VANCOUVER, British Columbia, Dec. 29, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is pleased to file its audited financial statements for the year ended on August 31, 2023.

Following is a short list of the company’s achievements in the relevant period:

- PharmAla became the first publicly traded company to produce GMP MDMA, and the first company to release its LaNeo™ GMP MDMA Drug Product- PharmAla became the first

PharmAla Files Audited Financials for Year Ending August 31, 2023

Fri, 29 Dec 2023 16:00:00 -0400

Following is a short list of the company’s achievements in the relevant period:

- PharmAla became the first publicly traded company to produce GMP MDMA, and the first company to release its LaNeo™ GMP MDMA Drug Product- PharmAla became the first

PharmAla Files Audited Financials for Year Ending August 31, 2023

Fri, 29 Dec 2023 16:00:00 -0400

Following is a short list of the company’s achievements in the relevant period:

- PharmAla became the first publicly traded company to produce GMP MDMA, and the first company to release its LaNeo™ GMP MDMA Drug Product- PharmAla became the first

PharmAla Files Audited Financials for Year Ending August 31, 2023

Fri, 29 Dec 2023 16:00:00 -0400

Following is a short list of the company’s achievements in the relevant period:

- PharmAla became the first publicly traded company to produce GMP MDMA, and the first company to release its LaNeo™ GMP MDMA Drug Product- PharmAla became the first

PharmAla Files Audited Financials for Year Ending August 31, 2023

Fri, 29 Dec 2023 16:00:00 -0400

Following is a short list of the company’s achievements in the relevant period:

- PharmAla became the first publicly traded company to produce GMP MDMA, and the first company to release its LaNeo™ GMP MDMA Drug Product- PharmAla became the first

PharmAla Files Audited Financials for Year Ending August 31, 2023

Fri, 29 Dec 2023 16:00:00 -0400

Following is a short list of the company’s achievements in the relevant period:

- PharmAla became the first publicly traded company to produce GMP MDMA, and the first company to release its LaNeo™ GMP MDMA Drug Product- PharmAla became the first

PharmAla Files Audited Financials for Year Ending August 31, 2023

Fri, 29 Dec 2023 16:00:00 -0400

Following is a short list of the company’s achievements in the relevant period:

- PharmAla became the first publicly traded company to produce GMP MDMA, and the first company to release its LaNeo™ GMP MDMA Drug Product- PharmAla became the first

PharmAla Files Audited Financials for Year Ending August 31, 2023

Fri, 29 Dec 2023 16:00:00 -0400

Following is a short list of the company’s achievements in the relevant period:

- PharmAla became the first publicly traded company to produce GMP MDMA, and the first company to release its LaNeo™ GMP MDMA Drug Product- PharmAla became the first

PharmAla Files Audited Financials for Year Ending August 31, 2023

Fri, 29 Dec 2023 16:00:00 -0400

Following is a short list of the company’s achievements in the relevant period:

- PharmAla became the first publicly traded company to produce GMP MDMA, and the first company to release its LaNeo™ GMP MDMA Drug Product- PharmAla became the first

PharmAla Files Audited Financials for Year Ending August 31, 2023

Fri, 29 Dec 2023 16:00:00 -0400

Following is a short list of the company’s achievements in the relevant period:

- PharmAla became the first publicly traded company to produce GMP MDMA, and the first company to release its LaNeo™ GMP MDMA Drug Product- PharmAla became the first

PharmAla Completes Historic First Shipment of MDMA and Psilocybin to Cortexa

Tue, 07 Nov 2023 08:55:00 -0400

VANCOUVER, British Columbia, Nov. 07, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is pleased to announce that it has completed its first shipment of MDMA and psilocybin to Cortexa, its 50:50 Australian Joint Venture with Vitura Health Limited (ASX: VIT). This shipment marks the first time that any molecules recently re-scheduled under the Authorized Prescriber Scheme were brought into Australia explicitly for use under that scheme, rather than for clinical trial purposes.

PharmAla Completes Historic First Shipment of MDMA and Psilocybin to Cortexa

Tue, 07 Nov 2023 08:55:00 -0400

PharmAla Completes Historic First Shipment of MDMA and Psilocybin to Cortexa

Tue, 07 Nov 2023 08:55:00 -0400